Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PWRV revoked:
https://www.sec.gov/litigation/admin/2017/34-82079.pdf
As warned, PWRV SEC Suspension for severely delinquent Financials/Filings:
https://www.sec.gov/litigation/suspensions/2017/34-81691.pdf
Order:
https://www.sec.gov/litigation/suspensions/2017/34-81691-o.pdf
Admin Proceeding:
https://www.sec.gov/litigation/admin/2017/34-81692.pdf
PWRV is severely delinquent in filing the company's Financials. The stock is at risk of an SEC Suspension and subsequent stock registration revocation.
https://www.sec.gov/cgi-bin/browse-edgar?company=Power+of+the+Dream+Ventures&owner=exclude&action=getcompany
not sure just had some unusual volume so I grabbed a few.
gm, just a shell or what?
Hi, where have you seen the news? This was a great potential with the genetic stuff, but the CEO of PWRV seems to have screwed it up for everyone. They should have never gone into PWRV, GI could have been doing great on its own.
They ran out of money, now trying to raise cash on a crowdfunding site
Hey guys, what's the word on PWRV? Been trying to do some research but haven't seen much on the boards recently. Anything of note happen lately?
Who would know, nothing coming from the company these days.
Hello, any news concerning PWRV? The last post by nagyiii transmitted very much hope about this stock, but nothing happened yet, and I read on another web-site that the company is currently seeking for an investor to acquire it (because of presumable lack of money-funds).
Regards,
Fabio
Hi All, I have great news from PWRV. My collegue just had a meeting with some guys from the company. He told that the company has started the negotiations about the marketing approval of DermaVir. The type C meeting papers are put together. The product is ready for the market, first might get a Breakthrough Therapy designation from the FDA. The collegue said that the company has now everything to get approval from FDA. All the clinical results are published at pubmed.com, we have checked. This stock is VERY undervalued, at $1 stock price the market cap is $45M. With the immune therapy for HIV... After they get a Breakthrough Therapy with the 45M trading stock what do you think would happen to the stock price????
Seems to be building again. No news from the company in ages.
There were over a 100,000 shares at the bid of .6 today. Most i've seen for a while.
Been in and out of this for about 3 years, so its on my screen which was showing some unusual trades the past week. I certainly didnt see yesterdays spike coming! But i will take it, there were over 500,000 shares at the bid of .12 which i can assure you is pretty rare in these parts. I was tempted to sell my current holding but didn't as something could be certainly a foot. Good luck.
What was the Heads up for you? You put that up the day before a spike.
I got in a few weeks ago based on a scan tool I made, after a run of weekly charts.
Thx.
03's would be a gift at this point ` $PWRV has been around for a while. I believe it's lift off ~
Not sure you will get those 03's now, something seems to be brewing...............
~PWRV~ looking for a rebuy in the .03's
Kind of interested in getting in any info from anyone will help?
~PWRV~ more green and prob. more tmrrw
There are certainly bigger bids today.
~PWRV~ Big Bids~ .07 here we come
You seem to be somewhat misguided?
~PWRV looks ready for a move up
~PWRV~ Run in progress
Looks like this is going down the tubes.......
3) Phase 2 Clinical trial results in 10K
2) Govt settlement of 5 to 20 million forthcoming
1) $31 million in assets listed in 10k = .80 price alone
And they are applying for Conditional Marketing Approval in the EU...that means possible revenue if approved. Very good.
10k filed. They have $31 Million in assets!!
Going a little lower. Re-visit 4.6 cents
They do have control over the website however...wonder when it is going to be updated....its been down for like 5 months
I recently wrote to the ceo, here is what I wrote and also his reply to me.........
Hello, many months have passed with no news whatsoever and the shareprice continues to fall, is there anything good happening? No news with IGLU or genetic immunity?
Hopefully something good is coming or we will see 5 cents again.
Regards ********
Unfortunately we have no control over the share price. We will issue press releases when appropriate.
In case people do not yet understand, we own the cure of HIV (among others.)
Thank you for your continued support.
This is a mistery. No buyers. Someone (or someones) picked up about 180K shares yesterday but nothing today.
Have any of you looked into Genetic Immunity at all? A truck load of independent information on their HIV vaccine out on the net.
I was not sure why no one was buying back in the iGlue days but this HIV vaccine is something else.
How come we have no buyers / investors here??????????????
This share price is insane, Give undervalued a whole new meaning.
any one around got L2 update for today?
Detonate, as you can see its not for the feint of heart! You must have filled your position? Shorts rule here until real positive news takes them out.
PWRV came to my attention when a friend who is heavily involved in the nanotechnology & medical field forwarded the below link to me.
I'd hoped to buy yesterday but the holding I need to sell first wasn't cooperating.
http://www.live-pr.com/en/print1049764344.htm
Detonate, how did you hear about this company? i'm just curious as it seems to have very little coverage. Take a position i think you will be happy you did further down the track.
You all take a look at this comparison chart of PWRV market cap with Genetic Immunity technology fully owned as compared to other therapeutic companies and their market caps.
Speaks for itself.
www.geneticimmunity.com
then click on the "For Investors Only Click Here" link at the bottom.
semantic43, Thank you for your post. I'm currently bidding on my first PWRV lot.
There doesn't seem to be a lot of activity on this board. One stock that I'm in has an active board and retail investors hold a ton of shares. Many of us put in GTC Sell Orders at a crazy high price to prevent brokerage houses from loaning out our shares.
Since the SEC is so ineffective a little vigilantism is in order. I'm hoping a few concerted efforts to create a some massive short squeezes will thin the shorter herd.
Simple. Company shorted to death by one or more market makers every single time there is a rise is share price. 3 million shares traded to get from 15 cents to 35 cents and then 400K shares to drop it to 20 cents in a matter of hours. Blatant manipulation.
Take a look at the short data:
http://www.otcshortreport.com/pwrv
Incredible buy opportunity. Buy the float kill the short.
I just learned about this company and plan to take a moderate position. While I'm glad I didn't buy at yesterday's prices I'm now concerned about today's dramatic drop.
Any enlightenment appreciated.
Followers
|
17
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
380
|
Created
|
10/10/08
|
Type
|
Free
|
Moderators |
Power of the Dream Ventures, Genetic Immunity Announces Positive Phase II Data for DermaVir HIV therapeutic Vaccine; Results Show 70% Viral Load Reduction
BUDAPEST, HUNGARY, Apr 11, 2011 (MARKETWIRE via COMTEX) -- Power of the Dream Ventures, Inc. (OTCBB: PWRV), Hungary's premier technology acquisition and development company, is pleased to announce Genetic Immunity's Phase II trial results for the Company's Lead Product candidate called DermaVir, based on a previously announced agreement whereby Power of the Dream Ventures will issue communications for Genetic Immunity on a going forward basis.
DermaVir, the world's first topical dendritic cell-targeting HIV therapeutic vaccine candidate, employs nanotechnology to boost the patient's own immune responses and to kill HIV-infected cells. The goal of DermaVir immune boosting therapy is to decrease antiretroviral drug exposure while maintaining undetectable HIV-RNA levels and achieve a remission (functional cure) in HIV-infected patients.
In a randomized, placebo-controlled, dose-ranging Phase II study conducted in Hamburg, Germany, thirty-six HIV-infected individuals, not yet taking antiretroviral drugs, received one of three DermaVir doses, or the placebo, every six weeks. "The treatments were very well-tolerated and CD4+ cell counts did not decrease," explained the study's Principle Investigator, Jan van Lunzen, MD of the University Medical Center Hamburg-Eppendorf, Infectious Diseases Unit. "At 24 weeks, the individuals' HIV viral loads were compared to their baseline values. A statistically significant reduction of 0.5 log10 copies/mL, a 70 percent reduction equivalent to that produced by several anti-HIV drugs, was seen in the cohort receiving 0.4 mg DermaVir vaccinations. Also in this group, HIV gag-specific precursor/memory T cells increased by 97 percent as the viral load decreased, a result not seen with antiretroviral drugs. Based upon our study the immune boosting and antiviral activity of DermaVir immunizations may provide a unique treatment approach for people with HIV/AIDS."
DermaVir features all key technological elements of Genetic Immunity's Immune Therapy Technology Platform. The Active Pharmaceutical Ingredient of DermaVir is a single plasmid DNA immunogen safely expressing 15 HIV antigens, the broadest antigen repertoire seen among HIV vaccine candidates to date. DermaVir Product is a "pathogen-like" nanomedicine and it is administered topically with a medical device, called DermaPrep. This technology in vivo targets the antigens to dendritic cells to prime naive T cells and expand the HIV-specific T cell pool to kill HIV-infected cells.
"Unlike traditional vaccines that prevent disease, therapeutic vaccines are given to people who are already infected to boost the body's immune response. To live a better and longer life, HIV-infected people boost their immune systems with vitamins, dietary supplements and herbs. We designed DermaVir to specifically boost their immune system to kill their HIV-infected cells and win the battle. Our Phase II trial provides the human proof of concept that immune boosting with DermaVir can reduce HIV viral load by killing the infected cells," said Julianna Lisziewicz, PhD and CEO of Genetic Immunity.
About PDV Power of the Dream Ventures, Inc. is a leading technology holding company. We identify and harness the unique technological prowess of Hungary's high-tech industry, turning promising ideas and ready to market products/technologies into global industry leaders. We focus on developing, acquiring, licensing, or co-developing technologies that originate exclusively in Hungary that are in prototype stage based on existing patents; in prototype stage prior to patenting; existing products that require expansion capital to commercialize; emerging science and high-technology research projects that require help in patenting, developing the product and marketing, University spin-off technologies, and ideas from the very early stage that represent "disruptive technologies." For more information, please visit http://www.powerofthedream.com
About Genetic Immunity
Genetic Immunity is a privately held US/Hungarian biotechnology company developing a new class of immunotherapeutic biologics for the treatment of viral infections, cancer and allergy. The Company's proprietary Immune Therapy Technology Platform is based on dendritic cell-targeting topical nanomedicines. For more information please visit http://www.geneticimmunity.com
About DermaVir
DermaVir is a novel therapeutic HIV vaccine with both antiviral and immunomodulating activities. Genetic Immunity believes that DermaVir has the potential to offer a paradigm change in the treatment of HIV/AIDS based on clinical data showing boosting of HIV-specific T cells and decrease of HIV-infected cells that are not eliminated by antiretroviral drugs. DermaVir has an excellent safety profile similar to vaccines used in healthy adults and children. The goal of DermaVir immune intensification is to modify HIV disease, decrease drug exposure while maintaining undetectable HIV-RNA levels and achieve remission (functional cure) in HIV-infected patients.
SOURCE: Power of the Dream Ventures, Inc.
Copyright 2011 Marketwire, Inc., All rights reserved.
-0-
SUBJECT CODE: Medical and Healthcare:Health and Nutrition
Medical and Healthcare:Healthcare
Medical and Healthcare:Surgery and Treatments
Pharmaceuticals and Biotech:Trials
Pharmaceuticals and Biotech:Drugs
Pharmaceuticals and Biotech:Equipment and Supplies
Pharmaceuticals and Biotech:Biotech
To best introduce the company, please see recent article.
Founded in August 2007 and with a staff of seven, iGlue calls itself "the superglue of the net" – and aims to be the future envy of Google.
Indexing internet pages (ring any bells?), iGlue uses technology to understand the semantic use of words and delivers related information based on text highlighted by the user.
Peter Vasko, chief executive of the three-year-old company behind iGlue In4 Kft, tells us his ambitions upon next month's launch – and reveals its closest competitor is owned by the Mountain View internet monolith Google.
• How are you funded?
"In4 Kft. [the company behind iGlue] specialises in the development of online applications based on university researches, with the participation of young university researchers. We are VC funded by Power of the Dream Ventures."
• How many users do you have now, and what's your target within
12 months?
"We launch in September 2010. In 12 months we want 250,000 users."
• Explain your business to my Mum.
"Imagine you're reading an article about the recession on bbc.co.uk. Maybe you want to know more about a person or place in the article. iGlue is a little box in your internet window that lets you double click any word on any web page to learn more about it. It will give you info, maps, links, videos, images and more right there without trawling round the internet for ages."
• How does that work?
"iGlue indexes the internet but it also understands the meaning of words. So when you search 'Kennedy' it can figure out from the article if you mean politician, airport or space station. It organises info and sorts the web, therefore 'wikifying' it in the process."
• How do you make money?
"We know that search traffic is one of the most valuable commodities on the web and we believe that we can get a chunk of that. By understanding our customers more deeply we will be able to provide a discreet and effective advertising model."
• How are you surviving the downturn?
"We have received our next round of funding and we are not focusing on our public launch in September so we're happy and busy."
• What's your background?
"Web developer, researcher but also a journalist, poet and a teacher. Either way, I always look for the spot from where the view on the world is the most exciting."
• What makes your business unique?
"IGlue completely changes people's interaction with online content. We provide a huge dynamic layer of content underneath any text on the web."
• What has been your biggest achievement or proudest moment so far?
"Without a doubt Geek'n Rolla 2010, organised by TechCrunch. Not just because of the second place, but we were amazed by the buzz around us during the public demo of iGlue in the exhibition room. After the conference, even the tech and hotel staff wanted to try it!"
• Who in the tech business inspires you?
"John von Neumann, Ted Nelson, Steve Wozniak."
• What's your biggest challenge?
"Since iGlue is Hungarian and based in Budapest, it's harder for us to compete with US companies vying for the attention of VC and press who are based across the Atlantic – but we're working on it!"
• What's the most important piece of software or web tool that you use each
day?
"Google Docs."
• Name your closest competitors.
"Apture, Open Calais, Freebase (Google), Evri."
• Where do you want the company to be in five years?
"In every web browser on the internet."
• Sell to Google, or be bigger than Google?
"Neither. Although we believe that we are building a product that will revolutionise the way people browse and experience the web. We really admire all the innovative hard work the guys at Google do. We would love to be in a position Google envies."
http://www.guardian.co.uk/technology/pda/2010/aug/27/iglue-semantic-web
----------------
Power of the Dream Ventures Announces Equity Commitment of up to $5,000,000
BUDAPEST, HUNGARY, Oct 09, 2008 (MARKET WIRE via COMTEX) -- Power of the Dream Ventures, Inc. (OTCBB: PWRV), Hungary's premier technology acquisition and development company, today announced that it has finalized a financing commitment of up to $5,000,000 from a YA Global Investments, L.P. The terms of the financing allow the Company to sell up to $5,000,000 in tranches of equity, based upon a specified discount to the market price of the Company shares, calculated over the five trading days following notice of an election to sell shares.
This financing commitment provides the Company with the capital necessary to continue the development of the Company's current technology portfolio and to acquire additional technologies.
"This commitment allows us to finish executing our business plan and bring to market a number of significant technologies we have been incubating. I believe this coming year will bring significant progress for us, including the launch of our iGlue software and RiverPower technologies, among others," commented Viktor Rozsnyay, CEO of the Company. "This commitment shows trust in the company and our business model. Now it's our turn to fully execute and provide return to our investors from technology commercialization revenues," Mr. Rozsnyay added.
In connection with the financing commitment, YA Global also acquired a warrant to purchase up to an additional 4,027,386 shares of common stock.
About Power of the Dream Ventures
Power of the Dream Ventures, Inc. is a leading technology holding company. We identify and harness the unique technological prowess of Hungary's high-tech industry, turning promising ideas and ready to market products/technologies into global industry leaders. We focus on developing, acquiring, licensing, and co-developing technologies that originate exclusively in Hungary that are in prototype stage based on existing patents; in prototype stage prior to patenting; existing products that require expansion capital to commercialize; emerging science and high-technology research projects that require help in patenting, developing the product and marketing, University spin-off technologies, and ideas from the very early stage that represent "disruptive technologies." We primarily focus on providing enabling solutions in the fields of environmental technologies, power generation and storage, software products and services, biotechnology, medical devices and what we call 'disruptive technologies.' For more information please visit our website at http://www.powerofthedream.com.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |